Two innovations in Karolinska Development's portfolio selected in an international innovation initiative
(Thomson Reuters ONE) -
STOCKHOLM - February 11, 2011 - In an international innovation initiative from
the Swedish Institute, 20 innovations have been selected as the most promising
in each of four different sectors. In the field of life science, four
innovations were selected, two of which are being developed by companies in
Karolinska Development's portfolio. One is a new chemical class of compounds
representing a novel therapeutic and diagnostic approach for the treatment of
Alzheimer's and other neurodegenerative diseases, the therapeutic part is being
developed by BioChromix Pharma (www.biochromixpharma.com). The other innovation
has resulted in new methods for safe biopsy sampling and safe early minimally
invasive treatment of cancer, this is being is developed by NeoDynamics
(www.neodynamics.se).
Press release from the Swedish Institute:
http://www.si.se/Svenska/Innehall/Pressnyheter/Nyheter-20102/Nyheter-2010/Nasta-
generation-innovationer-ska-satta-Sverige-pa-kartan/
Interview with Peter Åsberg, CEO of BioChromix Pharma, in Biotech Sweden:
http://biotech.idg.se/2.1763/1.367512/halla-dar-peter-asberg
Articles in Affärsvärlden and Ny Teknik:
http://www.nyteknik.se/nyheter/innovation/tillvaxtforetag/article3089698.ece
http://www.affarsvarlden.se/hem/nyheter/article3089697.ece
For further information, please contact:
Torbjörn Bjerke, CEO, Karolinska Development
Phone: +46 (0) 72 744 41 23
torbjorn.bjerke(at)karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development
Karolinska Development aims to create value for investors, patients, and
researchers by developing innovations from world class research into products
that can be sold or out-licensed with high returns. The business model is to:
SELECT the most commercially attractive medical innovations; DEVELOP these to
the stage where the greatest return on investment can be achieved; and
COMMERCIALIZE the innovations through the sale of companies or out licensing of
products. This will result in upfront payments, milestone payments and
royalties.
An exclusive deal flow agreement with Karolinska Innovations, along with
cooperation agreements with other leading Nordic universities, ensures the first
right of refusal to a continuous flow of innovations.
Karolinska Developments flexible exit strategy enables projects to be exited at
whichever stage of development offers the greatest return on investment, usually
after Phase II clinical trials have indicated the desired pharmaceutical effect
on patients - this being an important value enhancing step.
Today, the portfolio consists of over 40 projects at various stages, from
concept development to Phase II clinical trials, twelve projects are in clinical
trials with six in Phase II. The portfolio is particularly strong in the areas
of cancer, dermatology, inflammation, cardiovascular disease, women's health and
diseases that affect the central nervous system. www.karolinskadevelopment.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Karolinska Development AB (publ) via Thomson Reuters ONE
[HUG#1487159]
Unternehmensinformation / Kurzprofil:
Datum: 11.02.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 51351
Anzahl Zeichen: 3880
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 167 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Two innovations in Karolinska Development's portfolio selected in an international innovation initiative"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
